How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Rat Model Market
- By Rat Model Type: Spontaneous Rat Models, Induced Rat Models, Transgenic Rat Models, Knockout Rat Models, Humanized Rat Models
- By Disease Application: Oncology Models, Neurological Disorder Models, Cardiovascular Disease Models, Metabolic Disorder Models, Infectious Disease Models
- By Genetic Modification Technique: CRISPR/Cas9 Edited Rats, ZFN (Zinc Finger Nuclease) Rats, TALENs Modified Rats, RNAi Knockdown Rats, Conventional Gene Targeting Rats
- By Research Application: Pharmacology and Toxicology Testing, Behavioral Studies, Immunology Research, Regenerative Medicine, Drug Discovery and Development
- By Rat Strain: Sprague Dawley Rats, Wistar Rats, Long Evans Rats, Fischer 344 Rats, Lewis Rats
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Spontaneous Rat Models leads By Rat Model Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Rat Model Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Rat Model Type 5
Disease Application 5
Genetic Modification Technique 5
Research Application 5
Rat Strain 5
Companies profiled
Charles River Laboratories International Inc.
Envigo RMS LLC (a part of Inotiv)
Taconic Biosciences Inc.
Janvier Labs
Crown Bioscience Inc.
Oriental Yeast Co. Ltd.
Harlan Laboratories (now part of Envigo)
Biocytogen Co. Ltd.
SLC (SLC Japan Co. Ltd.)
CLEA Japan Inc.
Vital River Laboratories
Shanghai SLAC Laboratory Animal Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Envigo RMS LLC (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Taconic Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Janvier Labs
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Crown Bioscience Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Oriental Yeast Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Harlan Laboratories (now part of Envigo)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Biocytogen Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →SLC (SLC Japan Co. Ltd.)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CLEA Japan Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Vital River Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Shanghai SLAC Laboratory Animal Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →GemPharmatech Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Laboratory Animal Resources (LAR)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Envigo (formerly Harlan Laboratories)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,228M by 2033 · 10.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Spontaneous Rat Models38.3
- Induced Rat Models18.4
- Transgenic Rat Models16.0
- Knockout Rat Models18.1
- Humanized Rat Models9.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$949.6M → $2,270M · 11.5%
Europe$661.8M → $1,364M · 9.5%
Asia Pacific$604.3M → $1,409M · 11.2%
Latin America$374.1M → $880.8M · 11.3%
Middle East and Africa$287.8M → $623.3M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.092026
10.092027
10.112028
10.122029
10.132030
10.142031
10.152032
10.172033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.22.1
- Envigo RMS LLC (a part of Inotiv)15.9
- Taconic Biosciences Inc.3.9
- Janvier Labs8.9
- Crown Bioscience Inc.10.6
- Oriental Yeast Co. Ltd.10.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Rat Model Type11.9%
Disease Application16.0%
Genetic Modification Technique27.3%
Research Application30.1%
Rat Strain14.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe20.8
- Asia Pacific21.5
- Latin America13.5
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 92 | 83 | 79 | 95 | 74 | 87 | 85 |
| Envigo RMS LLC (a part of Inotiv) | 70 | 90 | 74 | 71 | 90 | 71 | 78 |
| Taconic Biosciences Inc. | 67 | 80 | 70 | 88 | 84 | 75 | 77 |
| Janvier Labs | 64 | 68 | 77 | 63 | 59 | 68 | 67 |
| Crown Bioscience Inc. | 54 | 54 | 71 | 75 | 59 | 60 | 62 |
| Oriental Yeast Co. Ltd. | 68 | 64 | 52 | 69 | 53 | 69 | 63 |
| Harlan Laboratories (now part of Envigo) | 62 | 53 | 62 | 40 | 58 | 41 | 53 |
| Biocytogen Co. Ltd. | 42 | 51 | 41 | 58 | 53 | 55 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Envigo RMS LLC (a part of Inotiv)
- Taconic Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Envigo RMS LLC (a part of Inotiv) | − | ✓ | ◐ | ✓ | ◐ | ✓ |
| Taconic Biosciences Inc. | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Janvier Labs | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| Crown Bioscience Inc. | − | ◐ | ◐ | ✓ | − | ◐ |
| Oriental Yeast Co. Ltd. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Harlan Laboratories (now part of Envigo) | ✓ | ◐ | ◐ | − | ◐ | − |
| Biocytogen Co. Ltd. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.85
2Envigo RMS LLC (a part of Inotiv)78
3Taconic Biosciences Inc.77
4Janvier Labs67
5Oriental Yeast Co. Ltd.63
6Crown Bioscience Inc.62
7Harlan Laboratories (now part of Envigo)53
8Biocytogen Co. Ltd.50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Envigo RMS LLC (a part of Inotiv)
Challenger2
Strong scale, closing on the leaders.
Taconic Biosciences Inc.Janvier Labs
Contender2
Focused players with pockets of strength.
Crown Bioscience Inc.Oriental Yeast Co. Ltd.
Niche2
Specialists in a single segment or region.
Harlan Laboratories (now part of Envigo)Biocytogen Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Rat Model Type in North America, then scale across Rat Model Market — a $241M beachhead inside a $4.25B market.
Beachhead (SOM)$241Mobtainable near-term
Serviceable (SAM)$1.70Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Spontaneous Rat Models
Best fit — highest urgency & budget in Rat Model Type.
Economic buyer79 fit
Induced Rat Models
Strong fit — clear ROI and a fast path to value.
End user66 fit
Transgenic Rat Models
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Rat Model Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Genetic Modification Technique
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Rat Model Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Rat Model Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation14%
Closed-won8%
$8.9KCAC
$37KLTV
4.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Rat Model Market is a resilient opportunity — $6.14B by 2033, compounding at 5.8%.
TAM · 2025$3.90Btoday
TAM · 2033$6.14Bforecast
CAGR5.8%2027–2033
Cumulative$44.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.14BTotal addressable market
SAM$2.18BServiceable available market
SOM$406MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.8% CAGR
Demand compounds through 2033, outpacing GDP across Rat Model Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Rat Model Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.14BLarge & growingTAM by 2033 at 5.8% CAGR
$2.18BServiceable nowreachable with today’s model
$406MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.79BBear3.8% CAGR
$6.14BBase5.8% CAGR
$7.86BBull7.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Rat Model Market — a $8.28B market by 2033. Plan: grow share from 7.0% to 13.8%.
Market size · 2033$8.28Btotal addressable
Market CAGR8.4%2027–2033
Target share13.8%from 7.0% today
Revenue ambition$1.14Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 13.8% | Behind |
| Revenue | $522M | $1.14B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 33.0% | 43.4% | On track |
| Customer retention | 87.5% | 93.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Rat Model Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Application capability
A defensible second engine — invest in Disease Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Rat Model Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $141M capacity & capability investment
- Greenlight bolt-on M&A in Disease Application
- Authorise North America expansion plan
- Fund R&D program for Rat Model Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Rat Model Market conversation — a $6.12B market you can size, segment and defend in minutes.
Market size · 2033$6.12Btotal opportunity
Growth4.9%CAGR to 2033
Addressable buyers1,383+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Rat Model Type
Goal Grow share in Rat Model Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 2 mopayback period
$50K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Envigo RMS LLC (a part of Inotiv)Taconic Biosciences Inc.Janvier LabsCrown Bioscience Inc.Oriental Yeast Co. Ltd.Harlan Laboratories (now part of Envigo)Biocytogen Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Rat Model Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Rat Model Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Fetal (Labor & Delivery) And Neonatal Care Equipment Market
Market size, share, segmentation and regional forecast.
$731M market · 2025 base year
View reportAntibody Production Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportOTC Hyaluronic Acid (HA) Market
Market size, share, segmentation and regional forecast.
$428M market · 2025 base year
View reportInsomnia Therapeutics Drugs Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCosmetic Surgical Surgery and Procedure Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportPharmaceutical Sterility Testing Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCranial Fixation and Stabilization Devices Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportMyeloproliferative Disorders Drugs Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportHuntington's Disease Treatment Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportInsulin Vials Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportExtracellular Matrix (ECM) Patches Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportInsulin Travel Case Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.